Page last updated: 2024-09-03

gefitinib and Dermatitis Medicamentosa

gefitinib has been researched along with Dermatitis Medicamentosa in 47 studies

Research

Studies (47)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	28 (59.57)	29.6817
2010's	16 (34.04)	24.3611
2020's	3 (6.38)	2.80

Authors

Authors	Studies
Fan, G; Li, Q; Liu, G; Liu, X; Lu, J; Shen, X; Wang, F; Wang, S; Zhu, H; Zhu, Y	1
Bortoluzzi, P; Giacalone, S; Marzano, AV; Nazzaro, G; Veraldi, S	1
Asawanonda, P; Chuenwipasakul, D; Rerknimitr, P; Wititsuwannakul, J	1
Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW	1
Boespflug, A; Kaya, A; Kaya, G; Saurat, JH; Saxer-Sekulic, N; Sorg, O; Thomas, L	1
Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S	1
Cheng, PS; Lai, FJ	1
Chiu, HC; Chiu, HY	1
Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J	1
Hisada, T; Imai, H; Ishihara, S; Ishizuka, T; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Seki, K; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Utsugi, M; Yamada, M; Yoshino, R	1
Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW	1
Choi, YS; Kong, SH; Seong, JY; Suh, HS	1
Dunsford, J	1
Lin, SS; Tsai, TH; Yang, HH	1
Aractingi, S; Nassar, D; Soutou, B	1
Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A	1
Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV	1
Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W	1
Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA	1
Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H	1
Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC	1
Cho, BC; Lee, JH; Park, JH; Shin, JU	1
Giaccone, G; Kirtschig, G; Scheffer, E; Stoof, TJ; Van Doorn, R	1
España, A; Fernandez-Galar, M; López-Picazo, JM	1
Bessis, D; Fabbro, M; Guillot, B; Jacot, W; Jorda, E; Pujol, JL; Ychou, M	1
Bañuls, J; Belinchon, I; Blanes, M; Massuti, B; Pascual, JC	1
Endo, K; Hirabayashi, M; Kurokawa, I	1
del Valle, ML; Sanz, A	1
Friberg, G; Kindler, HL; Skoog, L; Vokes, EE; Wade-Oliver, K	1
Elsner, J; Gutzmer, R; Kapp, A; Werfel, T	1
Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T	1
Treudler, R; Zouboulis, CC	1
Belinchón, I; Pascual, JC; Sivera, F; Yuste, A	1
Acebo, E; Díaz-Pérez, JL; Lasa, O; Martínez de Lagrán, Z; Ratón, JA	1
Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J	1
Sipples, R	1
Adams, D; Fernanadez, EM; Seiverling, EV	1
Aldanondo, I; Fernández-Guarino, M; Garrido, P; González-García, C; Jaén, P; Marquet, A; Pérez-García, B	1
Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P	1
Hsiao, YP; Shih, HC; Wu, MF; Yang, JH	1
Aldanondo Fernández de la Mora, I; Fernández-Guarino, M; García-Millán, C; Garrido López, P; Jaén Olasolo, P; Pérez García, B	1
Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO	1
Fernández-Guarino, M; Gónzalez-López, C; Olasolo, PJ; Pérez-García, B; Ryan, AM	1
Arpin, D; Balme, B; Becuwe, C; Dalle, S; Thomas, L	1
Blume, JE; Miller, CC	1
Chu, CY; Hsiao, CH; Sheen, YS	1
Burgin, S; Heidary, N; Naik, H	1

Reviews

7 review(s) available for gefitinib and Dermatitis Medicamentosa

Article	Year
Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature. Dermatology online journal, 2021, Feb-15, Volume: 27, Issue:2 Topics: Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Male; Scalp Dermatoses; Skin Diseases, Vesiculobullous	2021
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. Clinical journal of oncology nursing, 2008, Volume: 12, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index	2008
[Cutaneous side effects of EGFR inhibitors--appearance and management]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:4 Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines	2010
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Current opinion in oncology, 2011, Volume: 23, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2011
Common side effects of anti-EGFR therapy: acneform rash. Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1 Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index	2006
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines	2006
Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids	2008

Trials

4 trial(s) available for gefitinib and Dermatitis Medicamentosa

Article	Year
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment	2014
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)]. Voprosy onkologii, 2010, Volume: 56, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:8 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome	2011
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Eruptions; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Vomiting	2005

Other Studies

36 other study(ies) available for gefitinib and Dermatitis Medicamentosa

Article	Year
Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report. Anti-cancer drugs, 2022, 01-01, Volume: 33, Issue:1 Topics: Adenocarcinoma of Lung; Antihypertensive Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Eruptions; Female; Gefitinib; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lung Neoplasms; Lymphatic Metastasis; Middle Aged	2022
Gefitinib-associated lichen planus pigmentosus-like eruption. Dermatology online journal, 2021, May-15, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Female; Gefitinib; Humans; Hyperpigmentation; Lichen Planus; Lung Neoplasms; Middle Aged	2021
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases. JAMA dermatology, 2017, 09-01, Volume: 153, Issue:9 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines	2017
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH. Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:8 Topics: Antineoplastic Agents; Chloracne; Cytochrome P-450 CYP1A1; Dioxins; Drug Eruptions; Enzyme Activation; Epidermal Cyst; Erlotinib Hydrochloride; Female; Gefitinib; Hep G2 Cells; Humans; Male; Melanoma; Protein Kinase Inhibitors; Skin Neoplasms; Vemurafenib	2018
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study. Journal of the Indian Medical Association, 2012, Volume: 110, Issue:7 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome	2012
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses	2013
Scalp pustules in a patient receiving chemotherapy. JAMA, 2013, Sep-11, Volume: 310, Issue:10 Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp	2013
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4 Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Drug Monitoring; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Survival Analysis	2015
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer. JAMA dermatology, 2016, Volume: 152, Issue:3 Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies	2016
Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction. JAMA dermatology, 2016, 08-01, Volume: 152, Issue:8 Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Necrolytic Migratory Erythema; Protein Kinase Inhibitors; Quinazolines; Rare Diseases; Risk Assessment; Withholding Treatment	2016
Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis. Clinical and experimental dermatology, 2009, Volume: 34, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatomycoses; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Perineum; Quinazolines; Scalp Dermatoses; Treatment Outcome	2009
[Cutaneous side effects of EGF receptor inhibitors]. Bulletin du cancer, 2009, Volume: 96 Suppl Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin	2009
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Eruptions; ErbB Receptors; Exanthema; Gefitinib; Germ-Line Mutation; Humans; Infant; Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Young Adult	2010
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management. The Medical journal of Malaysia, 2012, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. Dermatology (Basel, Switzerland), 2012, Volume: 225, Issue:2 Topics: Acneiform Eruptions; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Tumor Cells, Cultured	2012
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. The British journal of dermatology, 2002, Volume: 147, Issue:3 Topics: Acneiform Eruptions; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines	2002
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clinical and experimental dermatology, 2004, Volume: 29, Issue:2 Topics: Acneiform Eruptions; Adenocarcinoma; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines	2004
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines	2004
Trichomegaly following treatment with gefitinib (ZD1839). The British journal of dermatology, 2004, Volume: 151, Issue:5 Topics: Antineoplastic Agents; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Hair Diseases; Humans; Middle Aged; Quinazolines	2004
Purpuric drug eruption possibly due to gefinitib (Iressa). International journal of dermatology, 2005, Volume: 44, Issue:2 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Ecchymosis; Female; Gefitinib; Humans; Purpura; Quinazolines	2005
A man whose scapula was spared a drug-associated rash. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Mar-15, Volume: 172, Issue:6 Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Neoplasms; Phrenic Nerve; Protein Kinase Inhibitors; Quinazolines; Scapula; Sebaceous Glands	2005
[Cutaneous side effects of EGF-receptor inhibition and their management]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2006, Volume: 57, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic	2006
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies	2005
Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures. Dermatology (Basel, Switzerland), 2005, Volume: 211, Issue:4 Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Cells, Cultured; Drug Eruptions; ErbB Receptors; Facial Dermatoses; Fatal Outcome; Gefitinib; Humans; Male; Protein-Tyrosine Kinases; Quinazolines; Skin; Stevens-Johnson Syndrome	2005
Severe cutaneous toxicity following treatment with gefitinib (ZD1839). The British journal of dermatology, 2005, Volume: 153, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Eruptions; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines	2005
[Acneiform eruption from epidermal growth factor receptor inhibitors]. Actas dermo-sifiliograficas, 2005, Volume: 96, Issue:7 Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines	2005
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:2 Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection	2006
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:4 Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Sulfacetamide; Triamcinolone	2006
[Gefitinib-induced perforating dermatosis]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Skin Ulcer	2006
Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer. The British journal of dermatology, 2006, Volume: 155, Issue:5 Topics: Acute Disease; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases, Vesiculobullous	2006
[Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Doxycycline; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2006
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors]. Nederlands tijdschrift voor geneeskunde, 2007, Apr-28, Volume: 151, Issue:17 Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines	2007
Necrotizing vasculitis due to gefitinib (Iressa). International journal of dermatology, 2007, Volume: 46, Issue:8 Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Skin; Vasculitis	2007
Exfoliative eruption secondary to gefitinib (ZD1839). Dermatology (Basel, Switzerland), 2007, Volume: 215, Issue:3 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines	2007
Livedo reticularis with retiform purpura associated with gefitinib (Iressa). International journal of dermatology, 2007, Volume: 46, Issue:12 Topics: Aged; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Livedo Reticularis; Male; Prostatic Neoplasms; Purpura; Quinazolines; Skin	2007
Severe purpuric xerotic dermatitis associated with gefitinib therapy. Archives of dermatology, 2008, Volume: 144, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erythema; Female; Gefitinib; Humans; Leg; Lung Neoplasms; Male; Purpura; Quinazolines	2008